SCHEMBL24252639

SCHEMBL24252639

Nc1cnnc2cc(-c3cc(B(O)O)ccc3OC(F)(F)C(F)F)ccc12

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.33
LRRK2 Q5S007 1/20 0.31
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25268259 0.95 PDE10A (0.31) PDE10ALRRK2
Formic Acid SCHEMBL30467779 0.95 PDE10A (0.31) PDE10ALRRK2
SCHEMBL26771277 0.92 PDE10A (0.34) PDE10ALRRK2
SCHEMBL24252763 0.89 PDE10A (0.35) PDE10ALRRK2
SCHEMBL25218806 0.88
SCHEMBL30467623 0.87 PDE10A (0.32) PDE10A
SCHEMBL24252384 0.87 PDE10A (0.32) PDE10A
SCHEMBL24252765 0.86 PDE10A (0.34) PDE10A
SCHEMBL24252258 0.86 PDE10A (0.34) PDE10ALRRK2
SCHEMBL24252632 0.84 PDE10A (0.33) PDE10ALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885LRRK2 1477/4885ALOX5AP 246/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PDE10A 1950/4885LRRK2 1477/4885ALOX5AP 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.